# US 2014/0155365 A1 · Compositions and methods for cytoprotection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155365 A1
- Document ID: US20140155365A1
- Status: Published application
- Kind: A1
- Application number: 14/174,669
- Filed: 2014-02-06
- Published: 2014-06-05
- Earliest claimed: 2007-03-27
- Assignees: Board of Trustees of the University of Arkansas
- Inventors: Alexei G. Basnakian; Richard B. Walker; John R.J. Sorenson
- Web page: https://patentgrep.com/patent/US20140155365A1

## CPC

- C07F 3/06: Zinc compounds
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 323/25: the carbon skeleton being acyclic and saturated
- C07C 323/58: with amino groups bound to the carbon skeleton
- C07C 323/59: with acylated amino groups bound to the carbon skeleton
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 277/06: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 277/14: Oxygen atoms
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.

## Claims

### Claim 1

A zinc chelate compound comprising at least one Zn ion and at least one ligand selected from the group consisting of a compound comprising Formula (I) and a compound comprising Formula (II), the compounds comprising Formulas (I) or (II) having the following structures:
wherein:
R1 is selected from the group consisting of hydrogen, phosphate, and acyl;
R2, R3, and R6 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;
R4 and R5 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl, or together R4 and R5 form ═O;
R1′ and R2′ are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl, or together R1′ and R2′ form a group selected from the group consisting of ═O, ═S, and a hydrocarbyl ring comprising from three to six members; and
R3′ and R4′ are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl, or together R3′ and R4′ form a group selected from the group consisting of ═O, ═S, and a hydrocarbyl ring comprising from three to six members.

### Claim 2 (depends on 1)

The zinc chelate compound of claim 1, wherein:
R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, alkylamino, carboxyl, carboxylate ester, and carboxamide;
R4 and R5 are independently selected from the group consisting of hydrogen, alkyl, carboxyl, carboxylate ester, and carboxamide, or together R4 and R5 form ═O; and
R6 is selected from the group consisting of hydrogen, carboxyl, alkyl, and acyl.

### Claim 3 (depends on 2)

The zinc chelate compound of claim 2, wherein each of R1, R2, R3, and R5 is hydrogen; R4 is COOH; and R6 is acetyl.

### Claim 4 (depends on 2)

The zinc chelate compound of claim 2, wherein each of R1, R2, R3, R4, R5, and R6 is hydrogen.

### Claim 5 (depends on 2)

The zinc chelate compound of claim 2, wherein each of R1, R2, R3, R5, and R6 is hydrogen; and R4 is COOH.

### Claim 6 (depends on 2)

The zinc chelate compound of claim 2, wherein each of R1 and R2 is hydrogen; R3 is methyl; together R4 and R5 form ═O; and R6 is CH2COOH.

### Claim 7 (depends on 2)

The zinc chelate compound of claim 2, wherein each of R1, R5, and R6 is hydrogen; each of R2 and R3 is methyl; and R4 is COOH.

### Claim 8 (depends on 1)

The zinc chelate compound of claim 1, wherein:
R1′ and R2′ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, and alkenyl, or together R1′ and R2′ form ═O; and
R3′ and R4′ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, and (CHOH)nCH2OH, or together R3 and R4 form ═O, and n is from 1 to 4.

### Claim 9 (depends on 8)

The zinc chelate compound of claim 8, wherein each of R1′, R2′, R3′, and R4′ is hydrogen.

### Claim 10 (depends on 8)

The zinc chelate compound of claim 8, wherein each of R1′ and R2′ is hydrogen, and together R3′ and R4′ form ═O.

### Claim 11 (depends on 8)

The zinc chelate compound of claim 8, wherein each of R1′, R2′, and R3′ is hydrogen, and R4′ is propyl.

### Claim 12 (depends on 8)

The zinc chelate compound of claim 8, wherein each of R1′, R2′, and R3′ is hydrogen, and R4′ is (CHOH)3CH2OH.

### Claim 13 (depends on 1)

The zinc chelate compound of claim 1, wherein the average ratio of ligand to zinc ion is from about 1:1 to about 2:1.

### Claim 14 (depends on 1)

The zinc chelate compound of claim 1, wherein the ligand has a first absorption maximum at about 205 nm and a second absorption maximum at about 230 nm, and the chelate has a first absorption maximum at about 210 nm and a second absorption maximum at about 225 nm.

### Claim 15 (depends on 1)

A composition comprising the zinc chelate compound of claim 1 and at least one pharmaceutically acceptable excipient.
